ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,610.00
0.00%
다우존스 지수
38,852.27
0.46%
Bitcoin
63,809.47
1.02%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Opiant Pharmaceuticals Inc (OPNT)

  7. Opiant Pharmaceuticals Inc (OPNT) 뉴스

OPNT

Opiant Pharmaceuticals (OPNT)

Opiant Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:OPNT
일자시간출처헤드라인심볼기업
2023/03/1319:16Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/1020:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0704:02Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:56Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:17Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:10Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:07Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0703:02Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:27Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:25Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:21Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:09Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0323:01Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/03/0322:57Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/2806:05Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/1707:14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0806:01GlobeNewswire Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0702:14Edgar (US Regulatory)Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0622:00GlobeNewswire Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCNASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0106:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0106:22Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/02/0106:20Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/01/2006:05GlobeNewswire Inc.Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseNASDAQ:OPNTOpiant Pharmaceuticals Inc
2023/01/1007:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OPNTOpiant Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:OPNT

최근 히스토리

FX
USDEUR
US Dollar vs Euro
USOTC
BASFY
BASF (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
NYSE
JPM
JP Morgan Chase
USOTC
ADDYY
Adidas (QX)
NYSE
MRK
Merck
FX
USDJPY
US Dollar vs Yen
USOTC
RHHBY
Roche (QX)
NYSE
VZ
Verizon Communications
NASDAQ
AAPL
Apple
COIN
SOLUSD
Solana
CCOM
US500
US 500
SPI
SP500
S&P 500
NYSE
NKE
Nike
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유